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Abstract
Background Active treatments for prostate cancer are well known to result in several adverse effects such as fatigue,
depression and anxiety symptoms, impacting the overall quality of life (QoL) and wellbeing of a considerable proportion of
patients. Resistance-based exercise interventions have shown positive effects to reduce or mitigate these treatment-related
side effects. However, the minimal dosage required to derive these benefits is unknown. We systematically reviewed the
resistance training effects in prostate cancer patients to determine the minimal dosage regarding the exercise components
(mode, duration, volume and intensity) on fatigue, QoL, depression and anxiety.
Methods Using PRISMA guidelines, MEDLINE, CINAHL, EMBASE, SPORTDiscus and Web of Science databases were
searched. Eligible randomised controlled trials examined prostate cancer patients undertaking resistance-based exercise
programs during or following treatment. Meta-analysis was undertaken when more than three studies were included.
Associations between resistance exercise components and its effects were tested by meta-regression analysis.
Results Eighteen trials involving 1112 men with prostate cancer were included. Resistance-based exercise programs resulted
in significant effects on fatigue (effect size=−0.3, 95% CI: −0.4 to −0.2, P < 0.001) and QoL (effect size= 0.2, 95% CI:
0.0 to 0.4, P= 0.018), with significant effects in specific questionnaires and domains of these outcomes. Resistance-based
exercise effects on depression (effect size=−0.3, 95% CI: −0.7 to 0.0) and anxiety symptoms (effect size=−0.3, 95% CI:
−0.5 to 0.0) were positive but not significant (P= 0.071 to 0.077). Meta-regression indicated no significant association
between resistance exercise components with fatigue and QoL outcomes (P= 0.186–0.689).
Conclusions Low volume resistance exercise undertaken at a moderate-to-high intensity is sufficient to achieve significant
fatigue and QoL benefits for men with prostate cancer and also mitigate depression and anxiety symptoms. A lower
resistance exercise dosage than usually prescribed may help enhance adherence by reducing exercise barriers.
Introduction
Several treatments are used to delay cancer progression and
enhance survival such as androgen deprivation therapy
(ADT) and radiotherapy in men with prostate cancer [1].
However, most patients are likely to face an array of
treatment-related adverse effects during and after the course
of treatment [2]. Among them, fatigue, depression and
anxiety symptoms affect ~20 to 40% of men with prostate
cancer undergoing primary treatment (e.g. surgery, radio-
therapy and ADT), impacting their overall quality of life
and wellbeing during and even following treatment [3–5].
Over the past decade, a substantial number of exercise
trials have reported significant benefits to quality of life and
fatigue in prostate cancer patients during ADT or following
treatment when undertaking resistance-based exercise [6–9]
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with some of them also presenting modest changes in
depression and anxiety symptoms [10, 11]. In the most
recent exercise guideline for cancer patients [12], a resis-
tance exercise prescription of two sets of 8–15 repetitions at
60–85% of one-repetition maximum (1-RM) in combina-
tion with aerobic exercise was recommended to counter
anxiety, fatigue and depressive symptoms. However, most
work underlying this recommendation was derived from
trials in breast cancer patients and survivors, and there is a
paucity of comparative trials regarding the resistance
training components. As a result, it is unclear if this would
be the most appropriate recommendation, especially in
prostate cancer patients. This may be especially the case as
to date there has only been a single trial comparing different
resistance training frequencies in this patient group [13].
The study of Norris et al. [13] compared resistance training
undertaken twice or three times per week for 12 weeks in
prostate cancer survivors and did not observe any differ-
ences in quality of life, fatigue, depression or anxiety
symptoms. The authors suggested that twice weekly train-
ing may be sufficient to provide benefits in these outcomes
given the time constraints and possible exacerbation of
symptoms such as fatigue related to undertaking exercise
3 days per week [13]. Although a promising result, it
remains unknown if a resistance training volume and
intensity, even lower than that previously suggested [12],
may represent a minimal and sufficient stimulus for
improvements in patient-reported outcomes in prostate
cancer patients at different treatment stages. This is
important given the role of resistance exercise to counter
treatment-related toxicities in men with prostate cancer
[2, 12]. Furthermore, despite several systematic reviews
examining exercise effects in prostate cancer patients
[14–19], none have addressed the minimal exercise dosage
required for improvements in common patient-reported
outcomes.
As a result, the aim of this review was to: (1) system-
atically review and analyse the resistance-based training
effects on fatigue, quality of life, depression and anxiety
outcomes in men with prostate cancer given their impor-
tance for patient wellbeing; and (2) examine the dose-
response relationship between the prescribed exercise
components (i.e. mode, duration, volume and intensity) and
responses on those outcomes.
Methods
Study selection procedure
The systematic review was undertaken in accordance with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [20, 21].
Furthermore, the method used was based on the minimum
criteria established by the Cochrane Back Review Group
(CBRG) [22].
This review included published data from randomised
controlled trials evaluating the effects of supervised
resistance-based exercise programs in prostate cancer
patients at any treatment stage (including post treatment).
The primary outcome for this review was fatigue, with
secondary outcomes of quality of life, depression and
anxiety. The exclusion criteria were: (1) home-based exer-
cise as the only intervention during the intervention period
due to lack of direct supervision and inability to quantify
training variables (e.g. kilograms used as a resistance with
resistance training machines or dumbbells in clinic-based
programs compared to elastic bands or bodyweight often
used in home-based programs); (2) trials involving mixed
cancer patients without specific information on the results
for prostate cancer patients; (3) trials not including or
reporting on the specific outcomes for this review, or did
not include sufficient information for analysis (e.g., baseline
and post-intervention assessment, or within- and between-
groups mean difference); and (4) written in a language other
than English. In the search strategy, titles and abstracts were
first independently evaluated. When abstracts did not pro-
vide sufficient information, they were selected for full-text
evaluation. Eligibility was assessed independently by two
reviewers, with differences resolved by consensus.
We included publications up to November 2019 using
the following electronic databases: MEDLINE, CINAHL,
EMBASE, SPORTDiscus and Web of Science. The terms
used were: ‘prostate cancer’ and ‘resistance training’ in
association with a list of sensitive terms (Supplementary
Material Table S1). In addition, we also performed a manual
search of the reference lists provided in the selected papers
as well as previous systematic reviews and meta-analytic
studies in patients with prostate cancer [14–19] to detect
studies potentially eligible for inclusion.
Data extraction
The data extraction was performed via a standardised form.
Clinical information of the patients such as age, disease
stage and treatment phase and intervention characteristics
that included duration, components of resistance training
such as prescribed modality, frequency, intensity and
volume, adherence (i.e. number of patients that completed
the program), attendance (i.e. number of sessions attended),
compliance (i.e. number of patients that successfully com-
pleted the exercise prescription) and adverse events were
extracted along with the main outcomes. Information was
always extracted for the longest period of the supervised
exercise intervention, while outcomes were extracted in
their absolute units (e.g., questionnaire scores).
P. Lopez et al.
Assessment of risk of bias
The risk of bias was evaluated according to the 2nd version
of the Cochrane risk-of-bias tool for randomised trials (RoB
2) [23] with each assessment focused at the outcome level.
The six-domain instrument includes: (1) randomisation
process; (2) deviation from intended interventions; (3)
missing outcome data; (4) measurement of the outcome; (5)
selection of the reported result and (6) overall bias. Overall
risk of bias was expressed as “low risk of bias” if all
domains were classified as low risk, “some concerns” if
some concern was raised in at least one domain but not
classified as at high risk in any other, or “high risk of bias”
if at least one domain was classified as high risk, or have
multiple domains with some concerns [23].
Data analysis
For the meta-analysis, the pooled effect estimates were
obtained from the standardised mean difference (SMD)
combining different questionnaire scores for the same
respective outcome, and mean difference (MD) for each
individual questionnaire, of baseline to the final assessment
corresponding to the period of the intervention. Analyses
were conducted for all studies and a subgroup analysis was
provided for low risk randomised controlled trials based on
RoB 2.0 when more than three studies were available.
Fatigue was assessed using the following instruments: the
Functional Assessment of Cancer Therapy—Fatigue
(FACT-F) [24], European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire C30—
Fatigue (EORTC QLQ-C30Fatigue) [25], Multidimensional
Fatigue Symptom Inventory-Short Form (MFSI-SF) [26],
Functional Assessment of Chronic Illness Therapy (FACIT)
[27], Brief Fatigue Inventory (BFI) [28], and the Schwartz
Cancer Fatigue Scale [29] questionnaires. The Functional
Assessment of Cancer Therapy—Prostate (FACT-P) and—
General (FACT-G) [30], the 36-Item Short-Form Health
Survey (SF-36) physical and mental health composite [31]
and EORTC QLQ-C30—Global [32] were used to assess
quality of life. The Center for Epidemiologic Studies (CES-
D) [33] and Brief Symptom Inventory-18—Depression
(BSI-18Depression) were used to assess depression, and the
BSI-18Anxiety [34] and Memorial Anxiety Scale for Prostate
Cancer (MAX-PC) [35] to assess anxiety. The ques-
tionnaires with their respective characteristics (number of
items, scaling and scores), minimally important difference
(MID) and cut-off points are described in Table 1. In
questionnaires reverse scaled for fatigue, depression and
anxiety outcomes, where higher values indicate better out-
comes rather than poorer outcomes, the mean in each group
was multiplied by −1 as recommended in the Cochrane
Handbook [36].
In studies with multiple exercise interventions vs. a single
control group, data from exercise groups was combined
according to the Cochrane Handbook [36]. Calculations were
performed using a random-effects model with the DerSimo-
nian & Laird method [37]. Statistical significance was
assumed when the mean difference effect reached an α value
≤0.05. Effect size (ES) were according to Cohen [38] with
values of 0.0 to <0.5 indicating small, values of 0.51 to <0.8
indicating medium, and values ≥0.8 indicating large effects.
Statistical heterogeneity was assessed using the Cochran Q
test [39]. A threshold P value of 0.1, as well as values greater
than 50% in I² were considered indicative of high hetero-
geneity [39]. We examined heterogeneity using sensitivity
analysis by omitting one study at a time. Publication bias was
explored by contour-enhanced funnel plots and Egger’s test
[40], and, if necessary, trim-and-fill computation was used to
estimate the effect of publication bias on the interpretation of
results [39, 41]. Analyses were conducted using the package
metan, confunnel, metabias, and metatrim from Stata
14.0 software (Stata, Texas, USA). Forest plots presented for
the outcome measures are after sensitivity analysis and/or
trim-and-fill procedure adjustments.
In addition, we tested the association between exercise
components (mode, intervention duration, prescribed
weekly volume and peak intensity) and SMD effects to
identify a dose-response relationship. Using one or multiple
variables at a time we assessed whether exercise compo-
nents influence the association of resistance-based exercise
with the main effects. Analyses were undertaken in out-
comes significantly affected by exercise provided the
models had more than 5 studies. For intervention duration,
prescribed weekly volume and peak intensity, analyses were
considered when the range was higher than 5%, while
exercise mode was coded as 0= resistance training alone
and 1= resistance training combined with other compo-
nents (e.g. aerobic, flexibility, impact-loadingor balance).
Correlations were weighted by the inverse of the variance of
each observation and the coefficient of determination (r2),
the statistical test of heterogeneity (I2), component coeffi-
cients, standard errors (SE) and 95% CI are presented for
each outcome with their respective P values. Analyses were
conducted using the package metareg from Stata 14.0 soft-
ware (Stata, College Station, USA).
Results
Studies included
Of the 1030 retrieved studies, 794 were retained for screening
after duplicate removals. Of these, 694 were excluded and
100 full-text articles were assessed for eligibility (Fig. 1) in
accordance with the inclusion criteria. The eligibility
What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic. . .
assessment resulted in 18 [refs. 6–8, 10, 11, 42–54] studies
that investigated the effect of resistance-based training (i.e.
resistance training alone, combined with aerobic exercise or
included in a multimodal exercise program) on patient-
reported outcomes in prostate cancer patients at any treatment
stage. Sixteen studies were included in the dose-response
Table 1 Patient reported outcome questionnaires for fatigue, quality of life, depression and anxiety.
Questionnaire Items and scaling Score MID Cut-
off point
Fatigue




3 pts [67] 34 pts [68]




NR 43 pts [69]
















5 pts [70] NR
EORTC QLQ-
C30Fatigue [25]




5 pts [71] NR
Quality of life




4 pts [67] 61.3 pts
[72]




















SF-36 [31] 36 items; 3-, 5- and 6-
point Likert rating scale
100
High—Better QoL
5 pts [77] NR
Depression




























BFI Brief Fatigue Inventory, BSI-18 Brief Symptom Inventory-18, CES-D Center for Epidemiologic Studies—Depression Scale, EORTC QLQ-
C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, FACIT Functional Assessment of Chronic
Illness Therapy, FACT-F Functional Assessment of Cancer Therapy—Fatigue, FACT-G Functional Assessment of Cancer Therapy—Genera,
FACT-P Functional Assessment of Cancer Therapy—Prostate, MAX-PC Memorial Anxiety Scale for Prostate Cance, MID minimally important
difference, MFSI-SF Multidimensional Fatigue Symptom Inventory-Short Form, NR not reported elsewhere, SF-36 36-Item Short-Form Health
Survey.
aScore based in the sum of FACT-G general score and the prostate cancer subscale.
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relationship analysis involving exercise mode, intervention
duration, prescribed weekly volume and peak intensity and
the effects on patient-reported outcomes.
Prostate cancer patients and exercise intervention
characteristics
A total of 1112 prostate cancer patients with an average age
of 69.6 ± 2.2 yrs participated in the included studies. Exer-
cise interventions were predominantly undertaken in
patients on ADT (14 of 18 studies) [6, 8, 10, 11, 42–44,
46–48, 50, 52–54]. Exercise modalities included pre-
dominantly combined resistance and aerobic training (8 of
18 studies) [6–8, 10, 44, 46, 50, 54], followed by multi-
modal exercise programs (6 of 18 studies)
[8, 11, 47, 49, 51, 53], and resistance training only (5 of
18 studies) [42, 43, 45, 48, 52] in a cohort of 555 patients
allocated to exercise intervention compared to 557 patients
in the control group. A total of 13 studies [6, 10, 11,
42–46, 48–51, 54] compared an exercise intervention vs.
usual care control, 4 [refs. 7, 47, 52, 53] were compared to a
home-based intervention involving aerobic or flexibility
training or to physical activity advice, and 1 [ref. 8] was
compared to a delayed exercise group. Studies character-
istics are shown in Table 2.
The mean exercise intervention duration was 17.3 ±
9.5 weeks with either 2 [refs. 6–8, 10, 11, 44–47, 49, 54] or 3.
sessions per week [42, 43, 48, 50–53] (average:
2.5 ± 0.8 sessions per week). The average total prescribed
resistance training volume was 8334 ± 4568 repetitions with a
weekly training volume of 489 ± 195 repetitions which is
equivalent to a training volume of 197 ± 58 repetitions
per session (~2 sets of 10 repetitions for 10 exercises). In
addition, the highest peak intensity reached throughout the
resistance training programs was 85% [6–8, 11, 48], followed
by 83% [52], 80% [45, 47, 49], 75% [50, 51], 70% [42, 43]
and 60% [46] of 1-RM. Information about resistance training
volume was not reported by two studies [44, 53], while four
studies [11, 44, 53, 54] did not report intensity. Exercise
program adherence ranged from 70 to 94% (reported in 6 of
18 studies) [11, 42, 45–47, 52], while the attendance and
compliance ranged from 65 to 94% (reported in 16 of
18 studies) [6–8, 10, 11, 42–45, 47, 49–54] and from 70 to
94% (reported in 5 of 18 studies) [44, 45, 49, 50, 53],
respectively. Supervised exercise sessions were conducted
in small groups of participants in seven studies
[6–8, 10, 45, 50, 51], while one study reported that exercise
sessions were conducted with one participant at a time [53].
Adverse events related to the exercise interventions were
identified in seven studies [7, 8, 11, 43, 49, 51, 54], while nine
studies [6, 44–47, 49, 51, 52, 54] reported no adverse events
during the intervention period, and 2 [refs. 11, 42] did not
report this information.
Risk of bias assessment
For the primary outcome of fatigue, 7.1% of the studies
presented some concern in risk of bias assessment (1 of
Fig. 1 Flow chart of study
selection process. Asterisk
indicates primary outcome.
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14 studies) [53]. The concern with the fatigue assessment
was due to the selection of the reported result as one study
did not report sufficient information for the outcome at
baseline (1 of 14, 7.1%; some concern) [53]. For the sec-
ondary outcomes, there was some concern of bias observed
in quality of life (13.3%, 2 of 15 studies) [11, 53],
depression (25.0%, 1 of 4 studies) [11] and for the anxiety
assessment (33.3%, 1 of 3 studies) [11]. The risk of bias
assessment for each outcome is shown in Table 3, while the
individual assessment is shown in Supplementary Material
Fig. S1.
Exercise effects on fatigue
For fatigue, exercise resulted in a significant overall mean
ES of −0.3 (95% CI: −0.4 to −0.2, P < 0.001) with I2=
0% in 507 prostate cancer patients who undertook exer-
cise interventions compared to 459 patients in control
groups (Fig. 2). The result was maintained in the subgroup
analysis involving the low risk studies. For questionnaires
used to assess patient-reported fatigue, positive effects of
−5.2 pts (95% CI: −10.1 to −0.2 pts, P= 0.040) were
found in the EORTC QLQ-C30Fatigue with I
2 = 31%, and
3.9 pts (95% CI: 2.6 to 5.3 pts, P < 0.001) with I2= 0% in
the FACT-F. When low risk subgroup analyses were
undertaken, all effects were maintained. There were
insufficient data for the MFSI-SF, FACIT, BFI and
Schwartz Cancer Fatigue Scale for further analysis. Hojan
et al. [50] was considered an outlier in the overall and
subgroup analysis for fatigue and for FACT-F being
omitted from the abovementioned results. No publication
bias was found (P= 0.327–0.455). Main effects along
with sensitivity and publication bias adjusted results are
presented in Table 4. The exercise effect in patients pre-
senting with high mean fatigue levels [54] was slightly
greater than that overall observed in overall fatigue (ES=
−0.4, 95% CI: −0.9 to 0.2).
In the dose-response analysis, the meta-regression mod-
els did not present significant associations between mode
(i.e. resistance training alone vs. resistance-based exercise
programs), duration (ranging from 8 to 60 weeks), resis-
tance training weekly volume (ranging from 320 to 975
repetitions) and peak intensity (ranging from 60 to 85% of
1-RM) with patient-reported fatigue (univariate: P=
0.055–0.988, multivariate: r2= 100%, P= 0.375, Table 5).
Exercise effects on quality of life
A significant improvement was observed in the quality of
life (ES= 0.2, 95% CI: 0.0 to 0.4, P= 0.014) in a sample of
447 prostate cancer patients who undertook resistance-
based exercise compared to 399 patients in control groups
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analysis (Table 4). Exercise also resulted in a positive effect
of 4.4 pts (95% CI: 1.7 to 7.2 pts, P= 0.002) in FACT-G
and 4.8 pts (95% CI: 3.1 to 6.5 pts, P < 0.001) in the FACT-
P with I2= 0 and 12%, respectively. Low risk subgroup
analysis indicated a positive effect of exercise on FACT-P
and FACT-G. In addition, exercise resulted in significant
effects in specific components of the SF-36 (i.e. physical
functioning, role physical, mental health composite, social
functioning and mental health, P= 0.003–0.020) as indi-
cated by the low risk subgroup analyses, while effects on
the EORTC QLQ-C30 components (i.e. emotional
functioning, cognitive functioning, and dyspnoea; P=
0.003–0.020) were observed in the overall and maintained
in the subgroup analysis. Outliers were identified in FACT-
G [50], FACT-P [43], SF-36Physical functioning and SF-36Mental
health composite [49], SF-36Vitality [6] and EORTC QLQ-
C30Emotional functioning [11] analyses and omitted from the
abovementioned results. No publication bias was observed
(P= 0.272–0.539). The main effects along with sensitivity
and publication bias adjusted results are presented in
Table 4. The exercise effects in patients presenting with low
mean quality of life values [50] were somewhat smaller than













Low risk 14 (100%) 14 (100%) 14 (100%) 14 (100%) 13 (92.9%) 13 (92.9%)
Some
concerns
0 0 0 0 1 (7.1%) 1 (7.1%)
High risk 0 0 0 0 0 0
Quality of life, n= 15
Low risk 14 (93.3%) 15 (100%) 15 (100%) 15 (100%) 14 (93.3%) 13 (86.7%)
Some
concerns
1 (6.7%) 0 0 0 1 (6.7%) 2 (13.3%)
High risk 0 0 0 0 0 0
Depression, n= 4
Low risk 3 (75.0%) 4 (100%) 4 (100%) 4 (100%) 4 (100%) 3 (75.0%)
Some
concerns
1 (25.0%) 0 0 0 0 1 (25.0%)
High risk 0 0 0 0 0 0
Anxiety, n= 3
Low risk 2 (66.7%) 3 (100%) 3 (100%) 3 (100%) 3 (100%) 2 (66.7%)
Some
concerns
1 (33.3%) 0 0 0 0 1 (33.3%)
High risk 0 0 0 0 0 0
n number of studies.
Fig. 2 Mean difference effects
of resistance-based exercise
compared with control on
fatigue. Overall and subgroup
analyses conducted with a
random-effects model. Grey and
white circles represent study
specific estimates based on risk
of bias assessment (Low risk,
and some concern or high risk of
bias, respectively); diamonds
represent pooled estimates of
random-effects meta-analysis.
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Table 4 Overall intervention effects on the patient-reported outcomes in prostate cancer patients.
Outcomes Analysis n Sample Mean difference 95% CI I2 Mean difference P value
Fatigue
Overalla Allb 12 896 −0.3 −0.4 to −0.2 0% <0.001
Low riskb 12 896 −0.3 −0.4 to −0.2 0% <0.001
FACT-F, ptsb Allb 6 474 3.9 2.6 to 5.3 0% <0.001
Low riskb 4 365 4.1 2.8 to 5.4 0% <0.001
EORTC QLQ-C30Fatigue All 5 396 −5.2 −10.1 to −0.2 31% 0.040
Low risk 5 396 −5.2 −10.1 to −0.2 31% 0.040
MFSI-SF Alld 1 20 −4.2 −17.6 to 9.2 – –
Low riskd 1 20 −4.2 −17.6 to 9.2 – –
FACIT-Fatigue Alld 2 113 3.6 1.2 to 6.0 – –
Low riskd 2 113 3.6 1.2 to 6.0 – –
BFI Alld 1 26 −0.8 −2.6 to 1.0 – –
Low riskd – – – – – –
Schwartz Cancer Fatigue Scale Alld 1 51 5.5 −3.1 to 14.0 – –
Low riskd 1 51 5.5 −3.1 to 14.0 – –
Quality of life
Overalla Allb 12 846 0.2 0.0 to 0.4 28% 0.014
Low riskb 11 716 0.2 0.0 to 0.4 32% 0.018
FACT-G Allb 4 187 4.4 1.7 to 7.2 0% 0.002
Low riskb 3 150 4.7 1.7 to 7.8 0% 0.002
FACT-P Allb 6 396 4.8 3.1 to 6.5 12% <0.001
Low riskb 5 359 6.3 3.8 to 8.7 0% <0.001
SF-36Physical health composite All 5 293 0.8 −0.7 to 2.3 45% 0.291
Low risk 5 293 0.8 −0.7 to 2.3 45% 0.291
SF-36Physical functioning All
b 5 287 1.9 0.7 to 3.2 0% 0.003
Low risk 5 287 1.9 0.7 to 3.2 0% 0.003
SF-36Role physical All 4 239 2.2 0.3 to 4.2 0% 0.025
Low risk 4 239 2.2 0.3 to 4.2 0% 0.025
SF-36Bodily pain All 4 239 −0.2 −2.5 to 2.1 16% 0.843
Low risk 4 239 −0.2 −2.5 to 2.1 16% 0.843
SF-36General health All 4 239 1.8 −0.5 to 4.0 30% 0.131
Low risk 4 239 1.8 −0.5 to 4.0 30% 0.131
SF-36Mental health composite All
b 4 239 2.9 1.2 to 4.7 0% 0.001
Low riskb 4 239 2.9 1.2 to 4.7 0% 0.001
SF-36Vitality All
b,c 6 450 0.2 −0.7 to 1.1 21% 0.655
Low riskb 6 450 0.2 −0.7 to 1.1 21% 0.655
SF-36Social functioning All 4 239 4.7 2.7 to 6.6 0% <0.001
Low risk 4 239 4.7 2.7 to 6.6 0% <0.001
SF-36Role emotional All 4 239 0.9 −1.0 to 2.8 0% 0.371
Low risk 4 239 0.9 −1.0 to 2.8 0% 0.371
SF-36Mental Health All 4 239 2.4 0.8 to 4.0 0% 0.004
Low risk 4 239 2.4 0.8 to 4.0 0% 0.004
EORTC QLQ-C30Global All 4 310 −0.1 −5.1 to 4.9 44% 0.980
Low risk 3 180 −1.3 −8.5 to 6.0 50% 0.731
EORTC QLQ-C30Physical functioning All
c 4 310 1.9 −0.6 to 4.5 35% 0.138
Low risk 3 180 3.1 −0.3 to 6.4 27% 0.073
EORTC QLQ-C30Role functioning All 4 310 5.0 −0.6 to 10.6 44% 0.080
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Table 4 (continued)
Outcomes Analysis n Sample Mean difference 95% CI I2 Mean difference P value
Low risk 3 106 8.5 −0.2 to 17.3 45% 0.057
EORTC QLQ-C30Emotional functioning All
b 3 180 6.1 1.0 to 11.2 5% 0.020
Low risk 3 180 6.1 1.0 to 11.2 5% 0.020
EORTC QLQ-C30Cognitive functioning All 4 310 4.9 1.7 to 8.1 39% 0.003
Low risk 3 180 6.2 0.5 to 11.9 29% 0.034
EORTC QLQ-C30Social functioning All 4 310 3.4 −1.7 to 8.4 0% 0.190
Low risk 3 180 3.5 −2.9 to 10.0 0% 0.282
EORTC QLQ-C30Nausea and vomiting All 3 180 −1.8 −4.1 to 0.5 14% 0.128
Low risk 3 180 −1.8 −4.1 to 0.5 14% 0.128
EORTC QLQ-C30Pain All 3 180 −4.3 −11.6 to 3.1 21% 0.258
Low risk 3 180 −4.3 −11.6 to 3.1 21% 0.258
EORTC QLQ-C30Dyspnoea All 3 180 −8.8 −16.0 to −1.6 0% 0.016
Low risk 3 180 −8.8 −16.0 to −1.6 0% 0.016
EORTC QLQ-C30Insomnia All 3 180 −5.0 −15.6 to 5.6 32% 0.358
Low risk 3 180 −5.0 −15.6 to 5.6 32% 0.358
EORTC QLQ-C30Appetite loss All 3 180 −0.5 −4.5 to 3.4 6% 0.789
Low risk 3 180 −0.5 −4.5 to 3.4 6% 0.789
EORTC QLQ-C30Constipation All 3 180 1.5 −3.7 to 6.8 0% 0.567
Low risk 3 180 1.5 −3.7 to 6.8 0% 0.567
EORTC QLQ-C30Diarrhoea All 3 180 0.8 −9.3 to 10.8 56% 0.878
Low risk 3 180 0.8 −9.3 to 10.8 56% 0.878
EORTC QLQ-C30Finance All
d 2 107 −0.9 −7.7 to 5.9 – –
Low riskd 2 107 −0.9 −7.7 to 5.9 – –
Depression
Overalla All 4 239 −0.2 −0.5 to 0.0 0% 0.091
Low risk 3 109 −0.3 −0.7 to 0.0 0% 0.077
CES-D Alld 2 156 −1.9 −3.8 to −0.1 – –
Low riskd 1 26 −2.8 −8.9 to 3.3 – –
BSI-18Depression All
d 2 83 −1.2 −2.1 to −0.2 – –
Low riskd 2 83 −1.2 −2.1 to −0.2 – –
Anxiety
Overalla All 3 212 −0.3 −0.5 to 0.0 0% 0.071
Low riskd 2 83 −0.1 −0.5 to 0.3 – –
BSI-18Anxiety All
d 2 83 −0.5 −1.2 to 0.2 – –
Low riskd 2 83 −0.5 −1.2 to 0.2 – –
MAX-PC Alld 1 129 2.5 0.4 to 4.6 – –
Low riskd – – – – – –
Questionnaires reverse scaled (High scores—Less fatigue).
BFI Brief Fatigue Inventory, BSI-18 Brief Symptom Inventory-18, CES-D Center for Epidemiologic Studies—Depression Scale, EORTC QLQ-
C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, FACIT Functional Assessment of Chronic
Illness Therapy, FACT-F Functional Assessment of Cancer Therapy—Fatigue, FACT-G Functional Assessment of Cancer Therapy—General,
FACT-P Functional Assessment of Cancer Therapy—Prostate, MAX-PC Memorial Anxiety Scale for Prostate Cancer, MFSI-SF Multidimensional
Fatigue Symptom Inventory-Short Form, n number of comparisons, SF-36 36-Item Short-Form Health Survey.
aAnalysis performed using standardized mean difference effect.
bAdjustment after sensitivity analysis omitting one study at a time.
cTrim-and-fill adjustment after significant effect of publication bias in Egger’s test (P < 0.1).
dInsufficient data for analysis.
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that overall observed in overall quality of life (ES= 0.1,
95% CI: −0.4 to 0.6).
In the dose-response analysis, the meta-regression mod-
els did not present significant associations between mode
(i.e. resistance training alone vs. resistance-based exercise
programs), duration (ranging from 8 to 60 weeks), resis-
tance training weekly volume (ranging from 240 to 975
repetitions) and peak intensity (ranging from 70 to 85% of
1-RM) with effects on patient-reported quality of life (uni-
variate: P= 0.096–0.322, multivariate: r2=−6.8%, P=
0.509, Table 5).
Exercise effects on depression and anxiety
symptoms
There was no significant exercise effect for overall
depression and overall anxiety (ES=−0.2, 95% CI: −0.5
to 0.0. P= 0.091 and ES=−0.3, 95% CI: −0.5 to 0.0, P=
0.071, respectively; Table 4 and Fig. 4). The heterogeneity
was I2= 0% with no effect of publication bias (P=
0.717–0.815). Effects on overall depression were main-
tained in the subgroup analysis, while not conducted on
anxiety given the small number of studies included. There
were insufficient data for the dose-response analysis in
depression and anxiety outcomes.
Discussion
The present review examined the resistance training effect
and dose-response on common patient-reported outcomes in
prostate cancer patients. The main findings were: (1)
supervised resistance exercise produced significant positive
benefits on overall fatigue and quality of life whether
undertaken as a sole exercise mode or combined with other
exercise modes; and (2) the beneficial effects on fatigue and
quality of life were independent of the prescribed exercise
volume and intensity undertaken. In addition, exercise
effects on overall depression and anxiety outcomes were
positive, although not significant. These results are clini-
cally relevant and demonstrate the potential to use a lower
weekly volume and moderate intensity exercise as a strategy
to improve quality of life and reduce cancer-related fatigue
during and following active treatment.
Fatigue is one of the most reported symptoms in prostate
cancer patients [3]. Considering its multifactorial nature,
fatigue is examined via physical, social, emotional and
functional wellbeing aspects in several questionnaires. In the
present review, a positive exercise effect was indicated for
overall fatigue and there were increases beyond the minimally
important clinically difference in the FACT-F and EORTC
QLQ-C30Fatigue, a result sustained in the low risk randomised
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included in the present analysis generally presented low
baseline levels of fatigue which may indicate that patients
with greater fatigue may derive a greater benefit from exercise
[8]. Previous studies [8, 15, 55] are in accordance with the
present analysis, demonstrating changes of ~3 pts in the
EORTC QLQ-C30Fatigue [8] moderated by higher baseline
fatigue levels [8, 55]. Thus, the present findings suggest that
supervised resistance-based programs can reduce levels of
fatigue in prostate cancer patients at various disease stages
and it may well be that patients with high baseline levels of
fatigue may experience greater improvements as previously
reported [8, 55]. Furthermore, the lack of association between
resistance training dosage and its effects on overall fatigue
also indicates the potential of exercise medicine using a lower
exercise dosage to manage cancer-related fatigue. The bene-
fits to using a low dosage of resistance training (e.g. less
repetitions per exercise at a moderate to high intensity)
appears to be regardless of the intervention duration as short-
term programs (8 weeks) produced similar reductions in
overall fatigue to that achieved by longer duration interven-
tions (e.g. 60 weeks) in prostate cancer patients at different
treatment stages. Finally, our results also demonstrate similar
effects between different exercise modes as denoted by the
nonsignificant univariate meta-regression model. This result
agrees with a previous study [56] showing that resistance,
aerobic or combined resistance and aerobic exercise promotes
similar effects on cancer-related fatigue in cancer patients
(−0.21, −0.23 and −0.26 SMD, respectively) and demon-
strates the potential use of a low dosage even when resistance
exercise is prescribed as a single mode of exercise in men
with prostate cancer.
Overall quality of life was significantly improved in
prostate cancer patients who undertook supervised resistance-
based exercise programs. Our results are in accordance with
meta-analyses undertaken in healthy older adults [57] and
those with cancer [58, 59] where quality of life was assessed
using the SF-36 and FACT questionnaires. Furthermore, a
low resistance training dosage may culminate in comparable
Fig. 3 Mean difference effects
of resistance-based exercise
compared with control on
quality of life. Overall and
subgroup analyses conducted
with a random-effects model.
Grey and white circles represent
study specific estimates based on
risk of bias assessment (Low
risk, and some concern or high




Fig. 4 Mean difference effects of resistance-based exercise com-
pared with control on depression (A) and anxiety (B). Overall and
subgroup analyses conducted with a random-effects model. Grey and
white circles represent study specific estimates based on risk of bias
assessment (Low risk, and some concern or high risk of bias,
respectively); diamonds represent pooled estimates of random-effects
meta-analysis.
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effects to that achieved by higher dosages in quality of life as
noted by the nonsignificant meta-regression models. These
results concur with those of Sweegers et al. [59] who found
no difference in quality of life in cancer patients with varying
weekly exercise volumes and energy expenditures during or
following treatment. Importantly, the present findings suggest
that less repetitions per exercise at a moderate to high inten-
sity is sufficient to improve quality of life in prostate cancer
patients, which is smaller than the dosage currently proposed
for this outcome [12]. Therefore, these results are of impor-
tance for prostate cancer patients in different treatment phases
as it reduces the time required (and effort/energy expenditure
required) for exercise, which may permit higher attendance
and compliance along with sustained benefits in longer term
exercise programs.
The present analysis essentially included a small
number of studies involving non-depressed men with
prostate cancer as observed by the baseline values
reported [10, 11, 45, 52]. Despite comparable effects to
those observed in fatigue and quality of life, the exercise
effects on depression symptoms only approached statis-
tical significance, presenting similar effect sizes to studies
in other cancer populations [60] but smaller than that
observed when different clinical populations are pooled
[61]. As a result, despite the overall significant association
between resistance exercise and reduced depressive
symptoms observed previously [60, 61], larger and more
rigorous studies are necessary to clarify the effect of
resistance-based exercise on depression in men with
prostate cancer and include patients with existing
depression. In addition, whether combining resistance and
aerobic exercise accrues superior effects than resistance
training alone is yet to be determined.
The use of exercise medicine is important for prostate
cancer patients given the anxieties associated living with a
cancer diagnosis and fears regarding its progression [4, 5].
We did not observe significant anxiolytic effects of
resistance-based exercise programs in prostate cancer
patients, which contrasts with studies in older adults [62],
breast cancer patients [63] and other groups of cancer
patients [64]. The reasons for such differences could be
related to the few studies included in the analysis and
apparently low baseline anxiety values of men in these
studies. However, given this outcome approached statistical
significance (P= 0.071), it is possible to suggest that
exercise may in some cases counter anxiety, especially in
those patients with greater anxiety levels. This result is
important given the relatively high prevalence of this
symptom across the treatment spectrum [5], and the asso-
ciation of anxiety with poorer surgical outcomes [65].
Moreover, the number of studies included also precluded
further analysis regarding the exercise minimal dosage or
mode. Thus, it is not possible to examine if low dosages or
the prescription of resistance training alone may provide
meaningful effects in this outcome as observed in fatigue
and quality of life, or even in other types of cancer [63, 64].
The strengths of the present study include the large number
of trials and participants assessing different patient-report
outcomes, and the assessment of low risk studies. However,
there are also some limitations which are worthy of comment.
First, there were insufficient data to perform dose-response
analyses on the depression and anxiety outcomes. These were
both secondary outcomes in our analysis and in all exercise
trials where the recruitment was not based on depression or
anxiety levels. Studies designed to directly investigate these
outcomes in those with depression and anxiety are required to
determine the efficacy of exercise and its dosage in this
patient/survivorship group. Second, we used prescribed
instead of the complied exercise dosage given that this is
predominantly reported in the studies analysed. However,
reporting of complied dosage [12, 66] in future studies will
assist with better defining the upper and lower exercise pre-
scription thresholds. Third, the nature of supervised group
sessions may be considered a potential factor in some of the
included studies. Participants in supervised exercise group
sessions are likely to share experiences related to treatment as
well as develop camaraderie during the exercise program [8]
and, consequently, this may contribute to additional benefits
in these individual studies. Lastly, although most patients
included were on ADT, the lower heterogeneity within the
analyses may indicate that the response is quite similar fol-
lowing treatment.
Establishing the minimal-dose approach to enhance
patient-reported outcomes is challenging in the field of exer-
cise oncology. As far as are aware, this is the first study to
examine the resistance training dose-response on patient-
report outcomes in prostate cancer patients. Our findings
suggest that a low dosage (e.g. less repetitions per exercise
undertaken at a moderate to high intensity), less than that
proposed in the latest exercise guideline for cancer patients
[12], is sufficient to induce meaningful benefits for fatigue
and quality of life in patients during or following active
treatment. Furthermore, the present results regarding depres-
sion and anxiety outcomes are also promising, indicating the
potential use of resistance-based training to avoid further
psychological distress during and following active treatment.
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